---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-024732"
form_type: "8-K"
ticker: "AKTX"
cik: "0001541157"
company_name: "Akari Therapeutics Plc"
filed_at: "2025-08-19T23:59:59+00:00"
generated_at: "2026-05-17T11:26:52.059892+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "low"
source: SEC EDGAR
---

# Akari Therapeutics posts updated investor presentation; details not disclosed

## Summary
- Company furnished an updated corporate presentation as Exhibit 99.1 on Form 8-K.
- Presentation will be used in meetings but no specific financial or strategic updates provided.
- No new material information available beyond the filing itself.

## SEC filing metadata
- accession: 0001641172-25-024732
- form_type: 8-K
- ticker: AKTX
- cik: 0001541157
- company_name: Akari Therapeutics Plc
- filed_at: 2025-08-19T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1541157/000164117225024732/0001641172-25-024732-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1541157/000164117225024732/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-024732
- JSON: https://secwatch.observer/filing/0001641172-25-024732.json
- Plain text: https://secwatch.observer/filing/0001641172-25-024732.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.